Day One achieved strong commercial momentum with OJEMDA net product revenue reaching $52.8 million in Q4 2025, contributing to a full-year total of $155.4 million. The company significantly reduced its net loss compared to the prior year and ended 2025 with a solid cash position of $441.1 million while expanding its oncology pipeline.

Day One Biopharmaceuticals demonstrated strong performance in Q2 2025, primarily driven by significant growth in OJEMDA net product revenue, which increased by 310% year-over-year. The company ended the quarter with a solid cash position and is on track with its clinical development programs, including the pivotal Phase 3 FIREFLY-2 trial.

Day One Biopharmaceuticals reported Q1 2025 financial results showing total revenue of $30.8 million, driven by OJEMDA net product revenue of $30.5 million. The company's net loss was $36.0 million, an improvement from the previous year. Day One ended the quarter with $473.0 million in cash, cash equivalents, and short-term investments.

Day One Biopharmaceuticals achieved significant growth in Q4 2024 with OJEMDA net product revenues reaching $29.0 million, contributing to a full year total of $57.2 million. The company ended 2024 with a strong cash position of $531.7 million, indicating a solid financial foundation for future growth and mission realization.

Day One Biopharmaceuticals, Inc. announced its third quarter 2024 financial results, featuring $20.1 million in OJEMDA net product revenue and $73.7 million in license revenue. The company ended the quarter with $558.4 million in cash, cash equivalents and short-term investments.

Day One Biopharmaceuticals reported strong early launch performance of OJEMDA, achieving $8.2 million in net product revenues during the initial two months, and made significant progress advancing its programs and pipeline, including the addition of DAY301.

Day One Biopharmaceuticals reported its first quarter 2024 financial results, including a net loss of $62.4 million and cash, cash equivalents, and short-term investments totaling $317.9 million.

Day One Biopharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting the upcoming PDUFA date for tovorafenib and continued advancement of the Phase 3 front-line trial. The company ended the year with $366.3 million in cash, providing runway into 2026.

Day One Biopharmaceuticals reported its third quarter 2023 financial results, highlighting the FDA's acceptance of the NDA for tovorafenib with Priority Review and a PDUFA target action date of April 30, 2024. The company's cash position remains strong, with sufficient resources to fund operations into 2026.

Day One Biopharmaceuticals announced its second quarter 2023 financial results, highlighting the initiation of the rolling submission of the tovorafenib NDA and updated data from the FIREFLY-1 trial presented at ASCO. A public offering was completed, raising $172.5 million and extending the cash runway into 2026.

Day One Biopharmaceuticals reported its first quarter 2023 financial results, featuring a cash position of $318.2 million, R&D expenses of $27.8 million, G&A expenses of $18.0 million, and a net loss of $42.4 million.

Day One Biopharmaceuticals reported its Q4 and full year 2022 financial results, highlighting the first patient dosed in the pivotal Phase 3 FIREFLY-2/LOGGIC trial and positive topline data from the Phase 2 FIREFLY-1 trial.

Day One Biopharmaceuticals reported financial results for the third quarter of 2022. They had cash, cash equivalents and short-term investments totaling $374.3 million on September 30, 2022. Research and development expenses were $22.0 million and general and administrative expenses were $17.7 million for the third quarter of 2022. Net loss totaled $37.8 million for the third quarter of 2022.

Day One Biopharmaceuticals announced positive initial data from the ongoing pivotal FIREFLY-1 study with tovorafenib in relapsed pLGG and raised $172.5 million in a follow-on public offering, which will fund the company into 2025.

Day One Biopharmaceuticals reported first quarter 2022 financial results. The company's cash and cash equivalents totaled $262.7 million. Net loss totaled $27.7 million for the quarter.

Day One Biopharmaceuticals reported fourth quarter 2021 financial results, with cash and cash equivalents totaling $284.3 million. Research and development expenses were $11.2 million, and general and administrative expenses were $10.8 million. Net loss totaled $21.9 million for the quarter.

Day One Biopharmaceuticals reported a net loss of $19.2 million for the third quarter of 2021. The company's cash and cash equivalents totaled $297.2 million as of September 30, 2021, which is expected to fund operations into the second half of 2023.

Day One Biopharmaceuticals reported a net loss of $15.5 million for the second quarter of 2021. The company's cash and cash equivalents totaled $310.0 million as of June 30, 2021, which is expected to fund operations into the second half of 2023.